The investigation of the factors affecting retroperitoneal lymph node metastasis in stage IIIC and IV epithelial ovarian cancer

2009 ◽  
Vol 280 (6) ◽  
pp. 939-944 ◽  
Author(s):  
Ali Yavuzcan ◽  
Ali Baloglu ◽  
Burcu Cetinkaya
2009 ◽  
Vol 19 (Suppl 2) ◽  
pp. S18-S20 ◽  
Author(s):  
Jonathan S. Berek

Introduction:Ovarian cancer spreads via the retroperitoneal lymphatics, and these lymph nodes frequently contain metastasis. A subset of patients whose disease was classified as stage IIIC has retroperitoneal lymph node metastases in the pelvic and/or para-aortic lymph nodes without intraperitoneal carcinomatosis and was upstaged from stage I to IIIB diseases based on these findings. Patients undergoing cytoreductive surgery for advanced-stage ovarian cancer undergo concomitant retroperitoneal lymphadenectomy in an effort to improve their survival.Methods:Stratification of patients with stage IIIC ovarian cancer by lymph node status and presence and extent of metastatic disease in the peritoneal cavity has been performed. Studies have determined the impact on disease-free and overall survivals of the resection of retroperitoneal lymph nodes as part of primary and secondary cytoreductive operations.Results:The overall survival of patients with stage IIIC ovarian cancer based on retroperitoneal lymph node metastasis without peritoneal carcinomatosis is 58% to 84% compared with 18% to 36% for those with macroscopic peritoneal carcinomatosis. Although the performance of a pelvic and para-aortic lymphadenectomy in patients with stage IIIC to IV diseases has been reported to prolong survival, an international randomized study did not confirm this finding. Patients who undergo secondary resection of isolated recurrent lymph node metastasis have a better survival than those with more extensive recurrent disease.Conclusions:These data support the stratification of patients with stage IIIC ovarian cancer based on the finding of metastasis to the retroperitoneal lymph nodes without peritoneal carcinomatosis versus those who have peritoneal carcinomatosis. The International Federation of Gynecology and Obstetrics Committee should consider modifying the ovarian cancer staging system by further stratifying stage III disease. Although systematic lymphadenectomy during primary cytoreductive surgery does not appear to improve overall survival, resection of isolated lymph node metastasis and recurrences in lymph nodes may be associated with a survival benefit.


2018 ◽  
Vol 41 (7-8) ◽  
pp. 444-448
Author(s):  
Baki Erdem ◽  
Ilkbal T. Yüksel ◽  
Nuri Peker ◽  
Suat C. Ulukent ◽  
Osman Aşıcıoğlu ◽  
...  

2010 ◽  
Vol 20 (3) ◽  
pp. 341-345 ◽  
Author(s):  
Hiroyuki Nomura ◽  
Hiroshi Tsuda ◽  
Nobuyuki Susumu ◽  
Takuma Fujii ◽  
Kouji Banno ◽  
...  

2013 ◽  
Vol 289 (5) ◽  
pp. 1087-1092 ◽  
Author(s):  
Volkan Ulker ◽  
Oguzhan Kuru ◽  
Ceyhun Numanoglu ◽  
Ozgur Akbayır ◽  
Ibrahim Polat ◽  
...  

2016 ◽  
Vol 27 (1) ◽  
pp. 22-27
Author(s):  
Chang Yang ◽  
Tianbo Liu ◽  
Bairong Xia ◽  
Lina Gu ◽  
Ge Lou

ObjectiveThis study aimed to reveal whether collagen triple helix repeat containing 1 (CTHRC1) was a predictor of peritoneal and lymph node metastases in epithelial ovarian cancer, which had not been researched by others previously.Materials and MethodsWestern blot analysis showed that dramatic overexpression of CTHRC1 could be seen in most metastatic tissues. Univariate and multivariate logistic regression analyses demonstrated that overexpression of CTHRC1 was linked with peritoneal dissemination and lymph node metastasis in epithelial ovarian cancer.ResultsThe negative and sensitivity-predictive values of CTHRC1 staining were excellent for both lymph node and peritoneal metastases. The odds ratio of high versus low staining for peritoneal dissemination was 2.250 (95% confidence interval, 1.126–4.496), and that for lymph node metastasis was 13.102 (95% confidence interval, 6.036–28.439).ConclusionsCollagen triple helix repeat containing 1 may potentially be used as a predictive marker of clinical progression in ovarian cancer either alone or in combination with other markers.


2001 ◽  
Vol 85 (7) ◽  
pp. 1032-1036 ◽  
Author(s):  
M Umemoto ◽  
Y Yokoyama ◽  
S Sato ◽  
S Tsuchida ◽  
F Al-Mulla ◽  
...  

2012 ◽  
Vol 125 ◽  
pp. S88-S89
Author(s):  
K. Matsuo ◽  
T. Sheridan ◽  
T. Miyake ◽  
K. Yoshino ◽  
K. Hew ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document